NervGen Pharma (NASDAQ:NGEN – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.05), Zacks reports.
NervGen Pharma Trading Up 4.3%
NASDAQ:NGEN traded up $0.08 during trading hours on Monday, hitting $1.96. 226,514 shares of the stock were exchanged, compared to its average volume of 514,211. NervGen Pharma has a 52-week low of $1.28 and a 52-week high of $6.30. The business’s fifty day simple moving average is $1.74. The firm has a market cap of $158.04 million and a P/E ratio of -4.26.
Analysts Set New Price Targets
Several equities research analysts recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of NervGen Pharma in a report on Monday, November 2nd. Wall Street Zen raised shares of NervGen Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, October 24th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.
View Our Latest Stock Report on NervGen Pharma
NervGen Pharma Company Profile
NervGen Pharma is a clinical-stage biotechnology company focused on developing treatments for nervous system injuries and diseases. The company’s research centers on ways to support nerve repair and restore function after damage to the nervous system. Its lead investigational product, NVG-291, is a peptide designed to target a protein involved in limiting nerve repair. NervGen has studied the candidate for spinal cord injury and is exploring its potential in other conditions involving nervous system damage.
Recommended Stories
- Five stocks we like better than NervGen Pharma
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
Receive News & Ratings for NervGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NervGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
